Brolucizumab and immunogenicity

Abstract

Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (Lond). 2020;34:611–3. Article Google Scholar Antonio Ligi. Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductionsvs-aflibercept . Accessed Mar 2020. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84. Article Google Scholar Clinical Updates: Beovu Update for ASRS Members. 2020. https://www.asrs.org/clinical/clinical-updates/960/Beovu-Update-for-ASRS-Members . Kuriakose A, Chirmule N, Nair P. Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res. 2016;2016:1298473. Article Google Scholar Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018;12:1625–35. Article CAS Google Scholar Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23:71–9. Article Google Scholar Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye. 2019. https://doi.org/10.1038/s41433-019-0722-6 . EXCLUSIVE: complaints prompt Intas to recall batch of biosimilar Razumab in India. 2020. https://www.moneycontrol.com/news/business/companies/exclusive-complaints-prompt-intas-to-recall-batch-of-biosimilar-razumab-in-india-2251273.html . Laird Harrison. New Batches of ranibizumab biosimilar safe, effective. 2020. https://www.medscape.com/viewarticle/867481 . Accessed Mar 2020. Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2020;34:614–5. Article Google Scholar Lioger B, Hennekinne F, Agier MS, Jonville-Bera AP, Maillot F. Incidence and characteristics of vasculitis associated with monoclonal antibodies and peptide fusion proteins: a survey from the French National Pharmacovigilance Database. Arthritis Rheumatol. 2016;68 suppl 10. https://acrabstracts.org/abstract/incidence-and-characteristics-of-vasculitis-associated-with-monoclonal-antibodies-and-peptide-fusion-proteins-a-survey-from-the-french-national-pharmacovigilance-database/ . Accessed 27 Feb 2020. Baldo B. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. OncoImmunology 2013;2:e26333. Article Google Scholar Isabwe GAC, Garcia Neuer M, de las Vecillas Sanchez L, Lynch D-M, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159–170.e2. Article CAS Google Scholar Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye. 2019;33:1359–61. Article Google Scholar Download references

Topics & Concepts